12/22/2020 8:20:48 AM
Bayer, Veracyte Announce Collaboration To Advance Precision Oncology Patient Identification Program In Thyroid Cancer
12/21/2020 8:26:14 AM
Veracyte Reports ISO 13485:2016 Certification For Its In Vitro Diagnostics Quality Management System
12/15/2020 8:18:22 AM
Veracyte Expands Collaboration With Lung Cancer Initiative
at Johnson & Johnson
9/14/2020 2:37:07 PM
Veracyte Promotes Richard Kloos To Executive Medical Director
9/11/2020 8:21:57 AM
Veracyte Initiates Consensus Study Exploring Medical Utility Of
Multiple Breast Cancer Genomic Tests
8/7/2020 4:28:11 PM
Veracyte Announces Closing Of Public Offering Of Common Stock
7/29/2020 8:21:01 AM
Veracyte And MAVIDx Agree To Develop Ultra-High Volume COVID-19 Testing On The NCounter System
7/27/2020 8:19:02 AM
Veracyte Appoints James Erlinger As EVP General Counsel And Secretary
6/11/2020 7:33:48 AM
Veracyte Says Clinical Utility Study Demonstrates Envisia Genomic Classifier's Ability To Improve IPF Diagnosis
5/14/2020 8:20:06 AM
CareDx And Veracyte Announce Partnership For Transplant Rejection
Testing On NCounter System
4/23/2020 8:20:56 AM
Veracyte And Yale Announce Exclusive License To Advance First Genomic Monitoring Test For Idiopathic Pulmonary Fibrosis
4/7/2020 8:18:29 AM
Veracyte Names Tracy Morris As VP Of Corporate Communications And Investor Relations
1/8/2020 8:22:01 AM
Veracyte Collaborates With Acerta Pharma On Oncology Therapeutics
11/2/2019 12:17:02 PM
Veracyte Announces New Data That Advance Understanding Of Genomic Alterations For Thyroid Cancer
5/2/2019 9:10:25 PM
Veracyte Prices Public Offering Of 5.50 Mln Shares At $23.25/shr
4/22/2019 8:38:17 AM
Veracyte Names Alfred Bowie VP, Corporate And Business Development
1/3/2019 7:10:03 AM
Veracyte Enters Strategic Collaboration With Johnson & Johnson Innovation In Battle Against Lung Cancer